FindTrial
Sign In

Use of evidence-based cardiovascular preventive therapies in type 2 diabetes patients with established or high risk of atherosclerotic cardiovascular disease

Use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors in type 2 diabetes patients with high or very high risk of atherosclerotic cardiovascular disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500101328
Enrollment
Unknown
Registered
2025-04-23
Start date
2024-08-20
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes with atherosclerotic cardiovascular disease

Interventions

type 2 diabetes (T2DM) patients with established or high risk of atherosclerotic cardiovascular disease (ASCVD):None

Sponsors

Xiamen Humanity Hospital, Fujian Medical University, Xiamen, Fujian, China.
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. type 2 diabetes 2. established or high risk of atherosclerotic cardiovascular disease 3. age =18

Exclusion criteria

Exclusion criteria: 1. Gestational diabetes, type 1 diabetes, other specific types of diabetes 2. diabetes acute complications: diabetic ketoacidosis, hyperosmolar hyperglycemia 3. severe hepatic and renal insufficiency and malignant tumor 4. life expectancy is less than 5 years 5. Pregnancy, lactation and mental illness

Design outcomes

Primary

MeasureTime frame
Trends of glucagon-like peptide-1 receptor agonist in type 2 diabetes patients with established or high risk of atherosclerotic cardiovascular disease;Trends of sodium glucose cotransporter-2 inhibitorsin in type 2 diabetes patients with established or high risk of atherosclerotic cardiovascular disease;—

Countries

China

Contacts

Public ContactYuhao Lin

Xiamen Humanity Hospital, Fujian Medical University, Xiamen, Fujian, China.

tzlinyuhao@163.com+86 592 526 2808

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026